American Diabetes Association

TABLE 3

Neutralization of TGF-β reverses the protective effect of oral anti-CD3 Ab in STZ-induced diabetes

Treatment			Incidence of diabetes	Blood glucose (mg/dl)
Feeding	IP		Incidence of diabetes	Blood glucose (mg/dl)
PBS		11/12	381 ± 87
Control IgG	Control IgG	10/12	394 ± 113
Control IgG	Anti–TGF-β Ab	10/12	355 ± 73
Anti-CD3 Ab	Control IgG	6/12^*	275 ± 73*
Anti-CD3 Ab	Anti–TGF-β Ab	11/12	358 ± 81

Treatment			Incidence of diabetes	Blood glucose (mg/dl)
Feeding	IP		Incidence of diabetes	Blood glucose (mg/dl)
PBS		11/12	381 ± 87
Control IgG	Control IgG	10/12	394 ± 113
Control IgG	Anti–TGF-β Ab	10/12	355 ± 73
Anti-CD3 Ab	Control IgG	6/12^*	275 ± 73*
Anti-CD3 Ab	Anti–TGF-β Ab	11/12	358 ± 81

Data are n or means ± SD from three experiments. Mice were fed with 50 μg anti-CD3 Ab and injected with STZ on days 1–5. Neutralizing anti–TGF-β Ab was injected intraperitoneally (IP) at days 0, 2, 4, 6, and 14. Blood glucose was measured at day 21.

P < 0.05, compared with other groups.

View Large

This Feature Is Available To Subscribers Only